Related Experiment Video

Updated: Aug 18, 2026

A Surgical Method for Subvalvular Structure Intervention Through a Transaortic Approach in Normal Bama Pigs
07:24

A Surgical Method for Subvalvular Structure Intervention Through a Transaortic Approach in Normal Bama Pigs

Published on: March 13, 2026

Septal myectomy for obstructive hypertrophic cardiomyopathy

Joseph A Dearani1, Gordon K Danielson

  • 1Mayo Clinic, Division of Cardiovascular Surgery, Rochester, MN 55905, USA.

Seminars in Thoracic and Cardiovascular Surgery. Pediatric Cardiac Surgery Annual
|April 9, 2005
PubMed

Insights

Septal myectomy is an effective surgical treatment for obstructive hypertrophic cardiomyopathy (HCM), significantly improving cardiac symptoms and reducing left ventricular outflow tract obstruction (LVOTO) in patients of all ages.

Area of Science:

  • Cardiology
  • Cardiac Surgery

Background:

  • Obstructive hypertrophic cardiomyopathy (HCM) causes significant symptoms and left ventricular outflow tract obstruction (LVOTO).
  • Septal myectomy is a surgical option for managing obstructive HCM.

Purpose of the Study:

  • To evaluate the efficacy and safety of septal myectomy in relieving LVOTO and improving symptoms in patients with obstructive HCM.
  • To compare long-term outcomes of septal myectomy with the natural history of nonoperated patients.

Main Methods:

  • Review of outcomes for adult and pediatric patients undergoing septal myectomy.
  • Assessment of echocardiographic LVOT gradients and symptomatic improvement.
  • Analysis of early and late mortality and long-term survivorship.

Main Results:

  • Septal myectomy effectively reduces LVOT gradients (median 0-5 mm Hg at follow-up) and improves cardiac symptoms in the majority of patients (90% improve by at least one functional class).
  • The procedure has low early mortality (0%-2.5%) and favorable long-term survivorship compared to nonoperated patients.
  • Simultaneous repair of associated cardiac lesions is feasible during myectomy.

Conclusions:

  • Septal myectomy is a safe and effective treatment for obstructive HCM, offering significant symptomatic relief and improved survival.
  • The procedure provides a valuable benchmark for evaluating emerging nonsurgical alternatives for obstructive HCM.

More Related Videos

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...